These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34698901)

  • 1. Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
    Hibma JE; O'Gorman M; Nepal S; Pawlak S; Ginman K; Pithavala YK
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):71-81. PubMed ID: 34698901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification.
    Igawa Y; Yoshida T; Makihara R; Torasawa M; Tateishi A; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    Lung Cancer; 2024 Oct; 196():107954. PubMed ID: 39303401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
    Chen J; Houk B; Pithavala YK; Ruiz-Garcia A
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):148-160. PubMed ID: 33449423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
    Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
    Lin S; Gong J; Canas GC; Winkle P; Pelletier K; LaBadie RR; Ginman K; Pithavala YK
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):235-245. PubMed ID: 35018553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
    Lee PH; Chen KC; Hsu KH; Huang YH; Tseng JS; Yang TY; Chang GC
    Anticancer Drugs; 2021 Nov; 32(10):1099-1104. PubMed ID: 34232936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.
    Chen J; Ruiz-Garcia A; James LP; Peltz G; Thurm H; Clancy J; Hibma J
    Clin Pharmacol Ther; 2021 Nov; 110(5):1273-1281. PubMed ID: 33973232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
    Chen J; O'Gorman MT; James LP; Klamerus KJ; Mugundu G; Pithavala YK
    Clin Pharmacokinet; 2021 Oct; 60(10):1313-1324. PubMed ID: 33937954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pragmatic guide for management of adverse events associated with lorlatinib.
    Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
    Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants.
    Li J; Pithavala YK; Gong J; LaBadie RR; Mfopou JK; Chen J
    Clin Pharmacokinet; 2021 Oct; 60(10):1303-1312. PubMed ID: 33937953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
    Soo RA; Huat Tan E; Hayashi H; Seto T; Lin CC; Ou SI; Kim DW; Liu G; Abbattista A; Martini JF; Hooi Wong C; Toffalorio F; Solomon BJ
    Lung Cancer; 2022 Jul; 169():67-76. PubMed ID: 35660971
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
    Sun S; Pithavala YK; Martini JF; Chen J
    J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
    Chen J; Xu H; Pawlak S; James LP; Peltz G; Lee K; Ginman K; Bergeron M; Pithavala YK
    Adv Ther; 2020 Feb; 37(2):745-758. PubMed ID: 31863284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
    Xu H; O'Gorman M; Boutros T; Brega N; Kantaridis C; Tan W; Bello A
    J Clin Pharmacol; 2015 Jan; 55(1):104-13. PubMed ID: 24990113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor.
    Gleue CA; Shah K; Wentworth A; Bridges A
    J Cutan Pathol; 2021 Mar; 48(3):425-428. PubMed ID: 33128468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
    BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.